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ABSTRACT: 
Infectious mastitis is a common condition among lactating women, with staphylococci and 
streptococci being the main aetiological agents. In this context, some lactobacilli strains isolated 
from breast milk appear to be particularly effective for treating mastitis and, therefore, constitute 
an attractive alternative to antibiotherapy. A 
1
H-NMR-based metabolomic approach was applied 
to detect metabolomic differences after consuming a probiotic strain (Lactobacillus salivarius 
PS2) in women with mastitis. Before 24 h urine of women with lactational mastitis was collected 
at baseline and after 21 days of probiotic (PB) administration. Multivariate (OSC-PLS-DA and 
hierarchical clustering) analysis showed metabolome differences after PB treatment. The 
discriminant metabolites detected at baseline of the intervention were lactose, and ibuprofen and 
acetaminophen (two pharmacological drugs commonly used for mastitis pain), while, after PB 
intake, creatine and the gut microbial co-metabolites hippurate and TMAO were detected. In 
addition, a voluntary desertion of the pharmacological drugs ibuprofen and acetaminophen was 
observed after probiotic administration. The application of NMR-based metabolomics enabled 
the identification of the overall effects of probiotic consumption among women suffering from 
mastitis and highlighted the potential of this approach in evaluating the outcomes of probiotics 
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consumption.To our knowledge; this is the first time that this approach has been applied in 
women with mastitis during lactation. 
Abreviations: A, acetaminophen; CFU, colony-forming unit; FID, Free induction decay ; HCA, 
Hierarchical cluster analysis; IB, ibuprofen; NMR, Nuclear Magnetic Resonance; OSC-PLSD-
DA, Orthogonal Signal Correction Partial Least Squares-Discriminant Analysis; PB, Probiotic; 
TMA, Trimethylamine; TMAO, Trimethylamine-N-oxide; TSP, 3-(trimethylsilyl)-proprionate-
2,2,3,3-d4. Keywords: Nutrimetabolomics, metabolic biomarker, mastitis, NMR, probiotics, 
Lactobacillus salivarius. 
 
1. Introduction 
 
Mastitis is a common disease during lactation with an incidence of up to 33% of lactating 
mothers [1], and 74–95 % of cases observed in the first three months post-partum [2]. This 
condition is usually defined as an inflammation of the mammary gland, characterized by a 
variety of local and, sometimes, systemic symptoms [3]. These symptoms of mastitis are 
accompanied by changes in the biochemical and immunological composition of milk, and in its 
sensorial properties. The infectious aetiology of lactational mastitis is usually so high that some 
authors define the term “mastitis” as an infectious process of the mammary gland, involving 
staphylococci, streptococci and/or corynebacteria[2,4]. Traditionally, Staphylococcus aureus has 
been considered as the main aetiological agent of acute mastitis, although Staphylococcus 
epidermidis is emerging as the leading cause of both subacute and chronic mastitis in human 
medicine [5-7]. Multiresistance to antibiotics and/or formation of biofilms is very common 
among clinical isolates of these two staphylococcal species. This explains why this condition 
used to be elusive to antibiotic therapy. In addition, maternal antibiotic therapy may disturb the 
normal microbiota of the respiratory and digestive tracts of the mother and breastfed infant pair, 
a fact that may itself further inhibit defence against infection[8]. Therefore, there is a need to 
develop strategies that represent an alternative to the use of antibiotics and, in this context; 
probiotics seem to be an appealing approach. Dysbiosis is the change in the balance of 
microbiota composition such that it may become harmful to host health [9]. Mammary dysbiosis 
may lead to mastitis, a condition that represents the first medical cause for undesired 
weaning[3,10]. Probiotics which have been defined by the WHO/FAO as “live microorganisms 
that when administered in adequate amounts confer a health benefit on the consumer, can 
potentially influence systemic health with several mechanisms of action [11].  In this regards, 
probiotics in several studies are focused of research [9].  Human milk is a source of bacteria to 
the infant gut. In addition, modulation of maternal gut microbiota during pregnancy and lactation 
could have a direct effect on infant health [10]. Recent studies indicate that the mammary gland 
contains its own microbiota during late pregnancy and lactation. Particularly, selected strains 
isolated from breast milk can be good candidates for use as probiotics [12,13]. Noticeably, 
probiotic bacteria that are originally isolated from human milk are specifically attractive 
organisms since they would fulfill some of the main criteria generally recommended for human 
probiotics, such as human origin, a history of safe prolonged intake by a particularly sensitive 
population (neonates, infants), and adaptation to mucosal and dairy substrates [14]. 
The advent of “-omics” approaches, particularly, metabolomics analysis promises to accelerate 
progress in our understanding to discern the molecular pathways and biochemical mechanisms 
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under the influence of the microbiota[15].
1
H-Nuclear Magnetic Resonance (
1
H-NMR) based on 
metabolomics, combined with multivariate statistical analysis, has proven to be a powerful 
technology for providing profiles of numerous components present in biological fluids, enabling 
non-discriminant, non-destructive, highly reproducible, high-throughput analysis[16].In this 
regard, metabolite profiling strategies have shown a remarkable potential to differentiate and 
characterize infectious diseases caused by microorganisms of different strains, species and 
genera [17], to obtain a metabolic footprint of microorganisms [18],and to assess the effects of 
probiotics on the mammalian metabolism[19]. This potential prompted us to examine the 
applicability of NMR-based metabolomics for identifying the metabolomics changes occurring 
in biofluids (i.e urine) of these women as a reflect of overall biochemical effects that could occur 
among women suffering from lactational mastitis after probiotic consumption, an approach that 
has not been documented so far. In this context, a metabolomic approach based on 
1
H-NMR 
spectroscopy coupled with multivariate statistical analysis was used in order to investigate the 
metabolite composition of urine samples collected from nursing women with mastitis, before and 
after the oral administration of the probiotic strain Lactobacillus salivarius PS2. 
 
2. Material and Methods 
2.1 Subjects and study design 
Initially, a total of 30 women with mastitis symptoms were screened and, of these, seven 
dropped out during the study. The reasons for dropping out, after the first analysis, were as 
follows: two women were suffering from severe anaemia (as assessed by blood analysis), four 
were taking antibiotics, and the last one moved to another country (Denmark) and could not 
deliver the final sample. Finally, 23 women finished the study (characteristics of the participants 
are reported in Suplementary Material, Table S1). All met the following criteria: breast 
inflammation, painful breastfeeding, milk bacterial count >3log10CFU/mL, and milk leukocyte 
count > 6 log10 cells/mL. None of them ingested commercial probiotic foods or supplements 
during the study. Women with mammary abscesses, Raynaud’s syndrome or any other mammary 
pathology were excluded. All volunteers gave written informed consent to the protocol, which 
was approved by the Ethical Committee of the Hospital Clínico of Madrid (Spain). The study 
was registered in the ClinicalTrials.gov database (NCT00716183). All volunteers were asked 
to follow a controlled diet for 48 h (see Supplementary Material, Table S2) before the collection 
of the samples in order to facilitate metabolite detection in the urine samples. Women were asked 
to fill in a record questionnaire related to the evolution of mastitis and the presence of any 
potential secondary effect of probiotic treatment. The records were used to monitor adherence to 
the study protocol. All the 23 women reported daily ingestion of a capsule over the 21 days with 
the exception of two women who reported ingestion over 20 days. 
The study lasted 21 days and, during this period, women consumed daily a capsule with 200 
mg of a freeze-dried probiotic (PB) containing ~9 log10 CFU of L. SalivariusPS2. The capsules 
were kept at 4 ºC throughout the study. Urine (24 h) samples from all the women were collected 
at the beginning (day 0, baseline) and at the end of the study (day 21, after PB) (See in 
Supplementary Material: Collection Procedures). 
 
2.2 Sample preparation  
A total of 46 urine samples (from the beginning and end of the intervention) from the 23 
women were analysed. The urine samples were thawed, vortexed and centrifuged at 13,200 rpm 
for 5 min. The supernatant (600 µl) from each urine sample was mixed with an internal standard 
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solution [120 μL, consisting of 0.1% TSP (3-(trimethylsilyl)-proprionate-2,2,3,3-d4, chemical 
shift reference), 2 mM of sodium azide (NaN3, bacteriostatic agent) and 1.5M KH2PO4, in 99% 
deuterium water (D2O)]. The optimized pH of the buffer was set at 7.0, with a potassium 
deuteroxide solution, to minimize variations in the chemical shifts of the NMR resonances [20]. 
This mixture was transferred to a 5 mm NMR tube. 
 
2.3 Urine 
1
H-NMR spectra acquisition and processing 
1
H-NMR spectra were acquired on a Varian Inova-500 MHz spectrometer (Varian Inc.) 
operating at a frequency of 500 MHz and a temperature of 298 K. A NOESY-presat pulse 
sequence was applied to suppress the residual water signal. FIDs were collected into 32 K data 
points (128 scans) with a spectral width of 14 ppm, an acquisition time of 2 s, relaxation delay of 
5 s, and a mixing time of 100 ms[20]. A 0.3 Hz line broadening function was applied to raw 
FIDs prior to Fourier transformation. The resulting NMR spectra were manually phased, baseline 
corrected and calibrated (TSP, 0.0ppm) using ACD Labs 1D NMR Processor 12.0 software 
(Advanced Chemistry Development Inc., Toronto, Canada). Prior to integration, each spectrum 
was segmented into 0.025 ppm chemical shift bins (buckets). The residual water resonance 
signal (δ 4.73 – 5.00) was excluded, and the resulting data set in the range from 0 to 10 ppm was 
then submitted to MetaboAnalyst 2.0, a web-based platform for comprehensive analysis of 
metabolomic data (www.metaboanalyst.ca). The matrix was row-wise normalized (rows were 
samples) by the sum of the intensities to reduce systematic bias during sample collection. 
 
 
2.4 Multivariate statistical analysis 
The multivariate analysis was performed using the SIMCA-P+13.0 software (Umetrics, Umea, 
Sweden). The data set was Pareto-scaled (each variable weighted according to 1/√SD), and then 
pre-processed using Orthogonal Signal Correction (OSC) filtration before PLS-DA analysis to 
reduce the variability not associated with the intervention effect [21,22]. The application of this 
filter was by a corresponding tool provided by SIMCA-P+13.0 software. The ability to classify 
each individual in the correct group was assessed by R
2
Y and the prediction power of the model 
was assessed by the Q
2
parameter. The OSC-PLS-DA model was calculated by a seven-round 
internal cross-validation of the data. Validation of the models and the evaluation of the degree of 
overfitting were then crucial to ensure that models were robust and not overfitted. For this 
purpose, a response permutation test (n = 200) was performed, and the correlation coefficient 
between the original Y and the permuted Y plotted against the cumulative R
2
 and Q
2
 was 
calculated. Generally the R
2
- and Q
2
-intercept limits for a valid model should be less than 0.4 
and 0.05, respectively[23]. 
Hierarchical clustering analysis (HCA), where distance between clusters in the multivariate 
space is measured according to Ward's aggregation method and sorted by size, was also applied 
and results were plotted as a tree plot. The contribution of the signals to the separation of the 
classes was visualized by using S-plot, which graphically combine the weight (p) of each 
metabolite within the model and its correlation (p(corr)) with the modelled class designation, 
thus helping in the selection of statistically significant and potentially relevant metabolites. 
Chemical shifts showing high correlation coefficients in the S-plots (p(corr) ≥ 0.5 and (p(corr) ≤-
0.5) arbitrary cut-off, previously adopted by our research group [21,24], were included in the list 
of candidate markers explaining the separation between baseline and after probiotic intake, 
which was then submitted to the metabolite identification procedure. 
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2.5 Metabolite identification 
Discriminant metabolites were identified using the Chenomx NMR Suite 7.5 (Chenomx Inc., 
Edmonton, Canada) library, by comparing NMR spectral data to those available in databases 
such as the Human Metabolome Database (HMDB; www.hmdb.ca), the Biological Magnetic 
Resonance Data Bank (BMRB, www.bmrb.wisc.edu) and the Madison Metabolomics 
Consortium Database (MMCD, mmcd.nmrfam.wisc.edu). Metabolites from acetaminophen and 
ibuprofen not available in such libraries and databases are identified by bibliographic support 
[25,26]. Further, Pearson’s correlation test was performed to assess correlations between signals 
corresponding to the same metabolite. Additionally, the Mann-Whitney test was used to test the 
significance for identified metabolites (p<0.05). 
 
 
3. Results 
 
3.1 Microbiological and clinical outcomes 
The staphylococcal/streptococcal mean count at day 0 was 3.60 log colony-forming units 
(CFU)/mL (3.34 – 3.85; 95% CI), while that after the probiotic treatment was 2.83 CFU/mL 
(2.59 – 3.07). This difference was statistically significant (p-value<0.001; Paired t student test, 
p<0.05). Clinically, most of the women (>85%) that participated in the assay had improved 
completely or notably after the administration of the probiotic strain. The evolution of the 
symptoms was evaluated at day 0 (baseline) and at the end of the study by midwives from 
womens’ health centres. At both times, the volunteers were asked to score their breast pain from 
0 (extremely painful) to 10 (no pain). At the end of the study, midwives reported that 18 women 
had no clinical symptoms of mastitis while the remaining 5 women had improved but still 
displayed mild symptoms. The mean score of breast pain reported by the women at day 0 was 
2.35  1.29 (SD), while it improved in all the participants at the end of the study (8.56  2.07).  
 
3.2 Multivariate analysis of urinary profile and metabolite identification 
A total number of 22 volunteers, after detecting and excluding one outlier spectral of a 
volunteer, were considered for analysis (Supplementary Material Figure S1). The OSC-PLS-DA 
analysis resulted in a model characterized by good robustness and predictability to explain the 
differences between the two sample periods, R
2
Y = 0.9 and Q
2 
= 0.7, respectively. In addition, a 
permutation test (n = 200) was carried out to validate the model. The y-axis intercept (R
2
 and Q
2
 
when the correlation coefficient is zero) is an indication of overfit. This test showed an R
2
 
intercept of 0.34 and a Q
2
 intercept of −0.16, validating the model. 
Figure 1.Tree plot of sample of hierarchical clustering analysis (HCA) with Ward’s aggregation 
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method and sorted by size. Samples of women with mastitis, at the beginning of the intervention 
(baseline), and after probiotic intake (after PB). 
 
The samples were subsequently analysed using a hierarchical cluster analysis (HCA), and closer 
inspection revealed that the clustering of groups corresponded to before (baseline cluster) and 
after probiotic intake periods (Figure 1).To better visualize the contribution of signals in the 
separation of the classes, an S-plot was used. The markers with higher p and p(corr) values were 
the most relevant signals. The lower-left quadrant of the S-plot in Figure 2 displays the most 
important signals in the urine samples at baseline (p(corr) ≤-0.5) and the upper-right quadrant of 
the S-plot displays the most important signals after PB intake p(corr) ≥0.5). The signals in the 
middle of the figure did not show any relevance in the model. The tentative metabolites 
identified between both time periods with p(corr) derived from the S-plot and the p-value from 
the Mann-Whitney test are shown in Table 1. 
 
 
 
 
Figure 2.S-plot associated with the OSC-PLS-DA score plot obtained in women with mastitis at 
the beginning of the intervention and after 21 days of probiotic intake intervention. The lower-
left quadrant of the S-plot displays the discriminative chemical shifts before the 21-day probiotic 
intervention (baseline) and the upper-right quadrant of the S-plot displays the discriminative 
chemical shifts after 21 days of intervention (after PB). Dashed lines mark the threshold for each 
period: p(corr)=+0.5 and p(corr)=-0.5. IB: ibuprofen+ ibuprofen metabolites. A: 
acetaminophen+ acetaminophen metabolites; TMAO: Trimethylamine-N-oxide. Lactose+IB+A 
indicates chemical shifts overlapped for lactose, ibuprofen and acetaminophen metabolites, 
achieving the greater values of the S-plot at baseline. 
 7 
 
Table 1.The significant metabolites derived from the S-plot in OSC-PLS-DA comparing women 
with mastitis at the beginning of the study (baseline) and after probiotic administration (after 
PB). ↑, indicates higher levels after probiotic intake (p[corr] ≥ 0.5); ↓, indicates lower levels after 
probiotic intake (p[corr] ≤ −0.5). *P-value from Mann-Whitney test. 
 
Metabolites Chemical shift 
(multiplicity) 
After PB Metabolic information p 
(corr) 
p* 
Lactose 3.55(m)
1
 ↓ Major carbohydrate present in 
breast milk  
-0.76 5.74x10
-7
 
3.66 (m)
1
 -0.57 6.59x10
-5
 
3.73 (t)
1
 -0.55 8.86x10
-5
 
3.85 (m)
1
 -0.57 0.001 
4.45(d, J=7.83Hz)
1
 -0.57 3.26x10
-5
 
4.67 (d, J=7.83Hz)
1
 -0.55 0.001 
5.23 (d, J=3.91Hz)
1
 -0.53 6.60x10
-5
 
IB/IB 
metabolite 
0.73 (d, J=6.60Hz)
2 ↓ Anti-inflammatory drug -0.56 0.002 
1.07 (d, J=6.60Hz)
2
 -0.68 1.68x10
-6
 
1.38 (d, J=7.12Hz)
2
 -0.67 5.16x10
-8
 
1.85(m)
2
 -0.57 3.00x10
-3
 
2.58(d,J=7.34Hz)
2
 -0.68 3.26x10
-5
 
2.84 (d, J=7.34Hz)
2 
-0.67 1.73x10
-4
 
3.50(s)
2
 -0.60 1.90x10
-4
 
A/A 
metabolites 
2.16 (s)
3 ↓ Analgesic drug -0.80 1.33x10-6 
7.13 (d, J=8.80Hz)
3 
-0.78 3.36x10
-6
 
Lactose+  
IB+ A 
3.62 (m)
 ‡
 ↓ - -0.89 1.77x10-8 
TMAO 3.27 (s)
4 ↑ Product of choline metabolism 
by gut microbiota 
0.72 2.65x10
-8
 
Hippurate
§
 7.56 (t, J=7.41Hz)
5 ↑ Glycine conjugate of benzoic 0.50 0.001 
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7.66 (t, J=7.41Hz)
5 acid associated with the 
microbial degradation of 
certain dietary components 
(gut microbiota co-metabolite) 
0.59 2.51x10
-4
 
8.54(br)
5 
0.52 0.002 
Creatine
§
 3.03 (s)
6 ↑ Energy maintenance 0.69 1.74x10-5 
Footnotes: PB: probiotic; *p<0.05, Mann-Whitney test; IB: ibuprofen; A: Acetaminophen; superscript 
numbers indicate correlation among the signals – same number indicates same metabolite with a 
correlation r≥0.90. 2These signals also correlate (r≥0.90) with other signals of IBU/IBU metabolites 
(δ0.85, δ1.21, δ5.56, δ 7.26, δ 7.31). 3These signals also correlate (r≥0.90) with other signals of A (δ5.10), 
TMAO: Trimethylamine-N-oxide; d:doublet, s:singlet, t:triplet.br:broad band. J: J-coupling value. 
‡
Overlapping signal: identifications match with Chenomx library and [25]; 
1,4,5,6: 
Identification match with 
Chenomx library and with standard compound from BMRB database. 
2, 3
identification agrees with [25] 
and [26] and HMDB spectra. 
§The chemical shift corresponding to creatine at δ3.93, as well as hippurate 
at δ3.96, not shown in this table, might be affected by interference of the ibuprofen and lactose 
resonances. Lactose+IB+A: chemical shifts overlapped containing lactose, ibuprofen and acetaminophen 
metabolites 
 
4. Discussion 
The baseline discriminant metabolites found in the urine of women with mastitis were lactose, 
ibuprofen and acetaminophen. Lactose is the major carbohydrate present in breast milk, 
providing a primary source of energy for infant growth. Moreover, its excretion in urine in 
pregnancy and lactation periods is well documented [27]. Excretion of lactose in urine is a 
measure of increased permeability of the lactating breast during inflammation [28]. Likewise, 
Fetherston et al. [28], in an attempt to identify possible predictors of mastitis in lactating mothers 
in the first three months post-partum, observed a significant elevation in the concentration of 
lactose in urine over a 24-hour period, with the highest levels observed when breast 
inflammation symptoms were more severe. These observations led to the conclusion that urinary 
excretion of lactose could be used as a reliable indicator of mastitis and a predictor of the degree 
and types of symptom experienced by mothers during this condition. Decreased concentration of 
lactose in urine following probiotic intake might, therefore, favourably affect the milk volume 
and the milk composition but may also represent an indicator of changes in breast physiology 
that allow the recovery of a mastitis mammary gland to its normal lactating state. 
Higher urinary excretion of ibuprofen (IB) and acetaminophen (A) and their metabolites at 
baseline, and lower urinary levels after 21 days, exhibited a free desertion (without a medical 
prescription) of the anti-inflammatory and analgesic drugs intake in women after probiotic 
administration. These pharmacological drugs are widely used in the amelioration of mastitis pain 
[2,29]. Additionally, acetaminophen, ibuprofen and their related metabolites are readily 
identifiable in 
1
H-NMR urine spectra, and their spectral signatures are distinctive in human 
urinary metabolome after their ingestion [25,30]. 
After PB administration, the discriminant metabolites found were trimethylamine-N-oxide, 
hippurate and creatine. Trimethylamine-N-oxide (TMAO) is an oxidation product of 
trimethylamine, and both are products of choline metabolism. Choline from the diet is converted 
by gut microbiota to form trimethylamine (TMA), which is mainly oxidized to TMAO [31]. 
Choline requirements are very important during pregnancy and lactation. The requirements of 
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choline are also likely to increase during pregnancy and lactation because large amounts of 
choline must be delivered to the foetus across the placenta [32] and secreted into breast milk [33] 
from maternal circulation. The increased levels of TMAO in urine could suggest a beneficial 
probiotic effect in the choline metabolism of the lactating women from the present study. 
Additionally, the presence of TMAO in human urine may also be related with high meat [34] and 
fish [35] intake. 
Many factors have been found to be associated with changes in the urinary excretion of 
hippurate (a metabolite strongly associated with diet and intestinal microbiota) [36]. To our 
knowledge, though, no studies evaluating women with mastitis have found a link with hippurate; 
however, a study of cows’ milk metabolites found lower levels of this metabolite in mastitis 
cows[37]. Thus, an increase in the levels of this metabolite after probiotic intake in urine could 
be reflected by increased levels of hippurate in milk, in consonance with an improvement in the 
health of women from the present study. 
Several studies have demonstrated the importance of gut microbiota in contributing to the 
excretion of metabolites such as TMAO and hippurate. For instance, their excretion was not 
observed in germ-free animals; however, after the exposure to intestinal microbiota, hippurate 
and TMAO excretion was detected [38]. Moreover, some studies reported a reduction in the 
urinary excretion of both hippurate and TMAO in rats treated with antibiotics [39,40]. In 
addition, this fact supports the non-antibiotic intake from the participants during the study. In this 
regard, research is ongoing concerning the important effects of gut microbiota on human health 
[41,42]. 
Finally, the creatine pool is important for maintaining ATP levels when energy demand is 
transiently greater than the rate of ATP synthesis [43]. Under physiological conditions, creatine 
is spontaneously converted to creatinine, which is subsequently excreted in urine [44]. However, 
elevated urinary levels of creatine and creatinine are also used as biomarkers of protein intake, 
associated with meat consumption [45]. 
A recent study reported a higher excretion of creatine in the breastfeeding stage, which 
indicates the ability of breastfeeding women to adjust to these metabolic demands imposed by 
breastfeeding [46]. The increased urinary level of creatine found after probiotic intervention 
could exhibit an increased endogenous synthesis of creatine and may reflect a re-establishment 
of the normal lactation stage in these women after the intervention. 
A possible lack of the present study is a proper control group of mastitis women without the 
administration of the probiotic. However, the objective of this study is to assess the urinary 
metabolomics changes in mastitis women before and after the probiotic administration. The 
amelioration of mastitis symptoms was previously tested in two randomly selected groups of 
women with mastitis: one group consuming probiotic and the other without probiotic 
administration (control group)[13], concluding that the probiotic administration appear to be an 
efficient alternative for the treatment of lactational infectious mastitis during lactation. 
5. Conclusions 
Characterization of the urine metabolic profile of the nursing women with mastitis at the end 
of the intervention by an NMR-based metabolomic approach showed that probiotic 
supplementation decreased lactose excretion which could suggesta normalization of breast 
permeability. Additional studies, examining the correlation of lactose with inflammatory and 
immunological mediators, along with the mother’s health status, are needed to confirm this 
possibility. 
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The reduction in the urine excretion of ibuprofen and acetaminophen demonstrates the 
voluntary desertion of anti-inflammatory and analgesic drugs intake in these women at the end of 
the study. Moreover, an increase of TMAO, creatine and hippurate might reflect changes in 
choline metabolism, in energetic pathways and in gut microbiota metabolism, in line with a 
reported improvement in the health status of the women at the end of the intervention. 
By profiling urinary metabolites we have demonstrated the applicability of NMR-based 
metabolomics for identifying the overall biochemical effects of oral probiotic administration to 
women suffering from lactational mastitis, and highlighted the potential of this approach in 
evaluating the outcomes of probiotics consumption. 
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